Boston Scientific Corporation
) continues to remain in the headlines with its innovations and
product launches. Recently, the company won the U.S. Food and
Drug Administration (FDA) approval for a bunch of defibrillators
and heart failure devices. According to the company, this latest
line of advanced devices will successfully help Boston Scientific
to further strengthen its foothold in the ever-growing and still
untapped cardiac medical devices market.
The aforementioned devices comprise the Mini family of
defibrillators including Dynagen Mini and Inogen Mini ICD, and
the X4 line of quadripolar CRT-Ds (cardiac resynchronisation
therapy with defibrillator function) - Dynagen X4 and Inogen
With the X4 line of quadripolar CRT-Ds which have the largest
battery capacity in the industry and sport a six-year warranty,
Boston Scientific expects to offer 70% more pacing options that
could effectively target the unmet need for high capture
thresholds and phrenic nerve stimulation. On the other hand, the
new Mini ICDs are claimed to be 20% smaller by volume and 24%
thinner than their competitive products thereby providing more
patient comfort. According to the company, these ICDs are helpful
in treating life-threatening arrhythmias of the heart.
With an abysmal number of nearly 400,000 out-of-hospital
cardiac arrests that occur each year in the U.S. alone, we expect
these newly approved products of Boston Scientific to
successfully address the untapped patient population and reduce
the cost of healthcare.
Despite challenging economic conditions, competitive
environment, pressure on core segments and a larger-than-expected
currency headwind, Boston Scientific has managed to successfully
move on with its strong pipeline of products.The company has
begun the year 2014 on a good note with the launch of the OffRoad
Re-Entry Catheter System in the U.S and the receipt of a CE mark
in Europe for its WallFlex Esophageal Stent in February.
Thereafter, Boston Scientific obtained the CE mark for
its REBEL Platinum Chromium Coronary Stent System and Ingevity
MRI Pacing Leads in March. Earlier this month, the company also
got the FDA and CE mark approval for the Expect Slimline (SL)
Needle which will be used for Endoscopic Ultrasound-Fine Needle
Aspiration (EUS-FNA) procedures.
Currently, Boston Scientific carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the medical product sector are
St. Jude Medical Inc.
). Enzymotec sports a Zacks Rank #1 (Strong Buy) while St. Jude
Medical and Edwards carry a Zacks Rank #2 (Buy).
BOSTON SCIENTIF (BSX): Free Stock Analysis
ENZYMOTEC LTD (ENZY): Free Stock Analysis
EDWARDS LIFESCI (EW): Free Stock Analysis
ST JUDE MEDICAL (STJ): Free Stock Analysis
To read this article on Zacks.com click here.